BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

875 related articles for article (PubMed ID: 9452329)

  • 1. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
    Holmberg B; Rosengren L; Karlsson JE; Johnels B
    Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders.
    Constantinescu R; Rosengren L; Johnels B; Zetterberg H; Holmberg B
    Parkinsonism Relat Disord; 2010 Feb; 16(2):142-5. PubMed ID: 19647470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes.
    Brettschneider J; Petzold A; Süssmuth SD; Landwehrmeyer GB; Ludolph AC; Kassubek J; Tumani H
    Mov Disord; 2006 Dec; 21(12):2224-7. PubMed ID: 17013909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy.
    Holmberg B; Johnels B; Blennow K; Rosengren L
    Mov Disord; 2003 Feb; 18(2):186-90. PubMed ID: 12539213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy.
    Nicoletti G; Lodi R; Condino F; Tonon C; Fera F; Malucelli E; Manners D; Zappia M; Morgante L; Barone P; Barbiroli B; Quattrone A
    Brain; 2006 Oct; 129(Pt 10):2679-87. PubMed ID: 16815875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease.
    Abdo WF; Bloem BR; Van Geel WJ; Esselink RA; Verbeek MM
    Neurobiol Aging; 2007 May; 28(5):742-7. PubMed ID: 16678934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy.
    Paviour DC; Thornton JS; Lees AJ; Jäger HR
    Mov Disord; 2007 Jan; 22(1):68-74. PubMed ID: 17089396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders.
    Constantinescu R; Zetterberg H; Holmberg B; Rosengren L
    Parkinsonism Relat Disord; 2009 Mar; 15(3):205-12. PubMed ID: 18562238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease.
    Nicoletti G; Tonon C; Lodi R; Condino F; Manners D; Malucelli E; Morelli M; Novellino F; Paglionico S; Lanza P; Messina D; Barone P; Morgante L; Zappia M; Barbiroli B; Quattrone A
    Mov Disord; 2008 Dec; 23(16):2370-6. PubMed ID: 18816803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New and reliable MRI diagnosis for progressive supranuclear palsy.
    Oba H; Yagishita A; Terada H; Barkovich AJ; Kutomi K; Yamauchi T; Furui S; Shimizu T; Uchigata M; Matsumura K; Sonoo M; Sakai M; Takada K; Harasawa A; Takeshita K; Kohtake H; Tanaka H; Suzuki S
    Neurology; 2005 Jun; 64(12):2050-5. PubMed ID: 15985570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic criteria for multiple system atrophy and progressive supranuclear palsy.
    Wenning GK; Colosimo C
    Rev Neurol (Paris); 2010 Oct; 166(10):829-33. PubMed ID: 20813385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-to-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy.
    Hussl A; Mahlknecht P; Scherfler C; Esterhammer R; Schocke M; Poewe W; Seppi K
    Mov Disord; 2010 Oct; 25(14):2444-9. PubMed ID: 20878992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease.
    Rizzo G; Martinelli P; Manners D; Scaglione C; Tonon C; Cortelli P; Malucelli E; Capellari S; Testa C; Parchi P; Montagna P; Barbiroli B; Lodi R
    Brain; 2008 Oct; 131(Pt 10):2690-700. PubMed ID: 18819991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
    Bukhatwa S; Zeng BY; Rose S; Jenner P
    Brain Res; 2010 Apr; 1326():174-83. PubMed ID: 20176003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy.
    Schulz JB; Skalej M; Wedekind D; Luft AR; Abele M; Voigt K; Dichgans J; Klockgether T
    Ann Neurol; 1999 Jan; 45(1):65-74. PubMed ID: 9894879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of Parkinson's disease and parkinsonism in northern Sweden: a population-based study.
    Linder J; Stenlund H; Forsgren L
    Mov Disord; 2010 Feb; 25(3):341-8. PubMed ID: 20108376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy.
    Petzold A; Thompson EJ; Keir G; Quinn N; Holmberg B; Dizdar N; Wenning GK; Rascol O; Tolosa E; Rosengren L
    J Neurol Sci; 2009 Apr; 279(1-2):76-9. PubMed ID: 19195665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.